InVitro International (IVRO)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
InVitro International (IVRO) trades at $0.09 with AI Score 49/100 (Grade C). InVitro International specializes in developing and supplying non-animal testing kits, including the Irritection Assay System and Corrositex, for product safety assessments across various industries. Market cap: $1.90M, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for IVRO: IVRO does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates IVRO against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
IVRO: the 1 perspectives are evenly split.
How is this calculated? →InVitro International (IVRO) Healthcare & Pipeline Overview
InVitro International (IVRO) is a Placentia, California-based specialist in non-animal testing kits, offering the Irritection Assay System for eye/skin irritation and Corrositex for chemical corrosiveness. Serving global manufacturers in cosmetics, pharmaceuticals, and chemicals, IVRO provides in vitro diagnostic tools and laboratory services, addressing the growing demand for alternative safety testing methods.
What Is the Investment Thesis for IVRO?
InVitro International operates within the specialized and growing market of non-animal in-vitro toxicology testing, a segment driven by increasing global regulatory pressures and ethical consumer demand to reduce animal testing. The company's proprietary Irritection Assay System and Corrositex products represent established solutions in this niche. Financially, InVitro International demonstrates strong operational efficiency with an impressive gross margin of 81.8% and a profit margin of 12.2%, indicating effective cost management relative to its revenue. The P/E ratio of 18.8 provides a valuation metric for this micro-cap entity. Key growth catalysts include the potential for expanded adoption of its testing systems as industries worldwide transition to alternative safety assessment methods. However, investors should note the company's small scale, with only 6 employees and a $1.90M market capitalization, alongside the higher risk profile associated with its OTC Other tier listing and negative Beta of -0.80, which suggests an inverse or weak correlation to broader market movements. Monitoring regulatory changes and market share acquisition in a competitive landscape remains crucial.
Based on FMP financials and quantitative analysis
IVRO Key Highlights
- Gross Margin of 81.8%, indicating strong cost control and profitability on products and services sold.
- Profit Margin of 12.2%, reflecting the company's ability to convert revenue into net income after all expenses.
- P/E Ratio of 18.8, providing a valuation multiple relative to the company's earnings per share.
- Market Capitalization of $1.90M, categorizing InVitro International as a micro-cap company.
- Lean operational structure with 6 employees, highlighting a highly specialized and focused workforce.
Who Are IVRO's Competitors?
IVRO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| PRE Prenetics Global Limited | $17.25 | +1.88% | $293.23M | 69 |
| EPGNY Epigenomics AG | $2.39 | +0.00% | 68 | |
| STRRP Star Equity Holdings, Inc. | $9.89 | -0.10% | $40.58M | 68 |
| TWST Twist Bioscience Corporation | $100.97 | +1.74% | $6.29B | 65 |
| CNTG Centogene N.V. | $0.33 | +100.00% | $9.42M | 50 |
| NVTA Invitae Corporation | $0.02 | -35.59% | $5.44M | 50 |
| ICLR ICON Public Limited Company | $170.94 | -1.23% | $13.09B | 50 |
| ME 23andMe Holding Co. | $0.61 | +100.00% | $15.31M | 50 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are IVRO's Key Strengths?
- Proprietary non-animal testing systems (Irritection, Corrositex) with established market presence.
- High gross margin of 81.8%, indicating strong product profitability and cost efficiency.
- Specialization in a niche, growing market driven by regulatory and ethical shifts.
- Long operating history since 1985, suggesting experience and reliability in its field.
What Are IVRO's Weaknesses?
- Small operational scale with only 6 employees and a $1.90M market capitalization.
- OTC Other tier listing, implying higher risk and potentially limited investor access.
- Unknown disclosure status, leading to a lack of comprehensive public financial information.
- Negative Beta of -0.80, which may indicate unusual market sensitivity or low correlation to broader market movements.
What Could Drive IVRO Stock Higher?
- Increased global regulatory mandates favoring non-animal testing, potentially expanding the addressable market for IVRO's products.
- Growing ethical consumer and industry demand for cruelty-free product development, driving adoption of in-vitro solutions.
- Potential expansion of product applications into new niche markets or specialized industrial segments.
- Continued provision of specialized independent laboratory services for irritation and corrosion assessments, generating recurring revenue.
What Are the Key Risks for IVRO?
- High risk profile due to OTC Other tier listing and unknown disclosure status, leading to limited transparency and liquidity.
- Intense competition within the in-vitro toxicology testing market from larger, better-resourced companies.
- Limited operational scale with only 6 employees and a $1.90M market cap, potentially restricting growth and R&D capabilities.
- Regulatory changes that could impact the adoption, validity, or required standards for current testing methods.
- Liquidity challenges inherent with OTC Other market trading, making it difficult for investors to buy or sell shares efficiently.
What Are the Growth Opportunities for IVRO?
- **Increasing Regulatory Adoption of Non-Animal Testing**: The global regulatory environment is progressively shifting towards mandating and encouraging non-animal testing methods for product safety assessments, particularly in the cosmetics, chemical, and pharmaceutical industries. This trend, observable in regions like the EU, US, and parts of Asia, directly expands the addressable market for InVitro International's Irritection and Corrositex systems. As companies worldwide adapt to new guidelines over the next 3-5 years, demand for proven in-vitro solutions like IVRO's is expected to rise, leveraging their established product efficacy and compliance capabilities.
- **Expansion into New Geographic Markets**: While InVitro International already serves global markets, there remains significant potential to deepen penetration in specific emerging economies or regions where regulatory frameworks regarding animal testing are either nascent or undergoing rapid evolution. This strategic expansion could involve establishing new distribution channels, forging local partnerships, or increasing direct sales efforts over the next 5-10 years. By proactively targeting these areas, IVRO can capitalize on early adoption trends and capture new customer bases for its existing, specialized product portfolio.
- **Diversification of Product Applications**: The Irritection and Corrositex systems are currently utilized across a broad range of industries. A key growth opportunity lies in identifying and targeting new, highly specific applications or niche product categories within existing sectors where irritation or corrosion testing is critically important. This could include specialized medical devices, advanced industrial materials, or novel consumer product formulations. By demonstrating the versatility and reliability of its existing solutions for these new uses, IVRO can expand its market footprint and revenue streams over the next 2-4 years.
- **Technological Advancements and System Enhancements**: Continuous investment in research and development to enhance the accuracy, efficiency, and throughput of the Irritection and Corrositex systems could significantly bolster InVitro International's competitive position. This might involve integrating cutting-edge technologies like artificial intelligence or machine learning for data analysis, or developing more sophisticated in-vitro models that offer even greater predictive power. Such advancements could lead to the introduction of upgraded product versions or new service offerings within 3-7 years, attracting new clients and reinforcing loyalty among existing ones.
- **Strategic Partnerships and Collaborations**: Forming strategic alliances with larger pharmaceutical companies, contract research organizations (CROs), or reputable academic institutions presents a substantial growth avenue. These collaborations could serve multiple purposes: accelerating market adoption through broader distribution networks, gaining access to advanced research capabilities, or facilitating the co-development of next-generation testing solutions. Such partnerships could unlock significant growth potential over the next 5-10 years by expanding InVitro International's reach, enhancing its credibility, and potentially diversifying its service offerings.
What Opportunities Does IVRO Have?
- Increasing global regulatory pressure to reduce animal testing, expanding the addressable market.
- Potential for expansion into new geographic markets or deeper penetration in existing ones.
- Diversification of product applications within existing or new industrial sectors.
- Strategic partnerships with larger entities to enhance distribution and market reach.
What Threats Does IVRO Face?
- Intense competition from other in-vitro testing companies and alternative methodologies.
- Evolving regulatory landscape that could require new testing standards or invalidate existing methods.
- Limited resources for research and development, potentially hindering innovation and competitive edge.
- Inherent risks associated with trading on the OTC Other market, including liquidity and transparency issues.
What Are IVRO's Competitive Advantages?
- Proprietary non-animal testing systems, Irritection Assay System and Corrositex, with established methodologies and market acceptance.
- Specialization in the niche market of in-vitro toxicology testing, offering focused expertise and solutions.
- Long operating history since 1985, indicating experience, brand recognition, and a proven track record in the industry.
- Benefiting from regulatory tailwinds and increasing ethical demand favoring non-animal testing, creating a structural demand advantage for its products.
What Does IVRO Do?
Established in 1985 and headquartered in Placentia, California, InVitro International has carved a niche in the biotechnology sector by specializing in the creation and supply of non-animal testing kits. The company's core mission revolves around providing ethical and scientifically sound alternatives to traditional animal testing, catering to markets both within the United States and globally. A cornerstone of their product portfolio is the Irritection Assay System, an advanced in vitro diagnostic tool. This system is meticulously designed to identify, categorize, and forecast the potential for eye and skin irritation across an extensive array of products, encompassing everything from cosmetics and general consumer goods to pharmaceuticals and diverse chemical raw materials. Complementing this, InVitro International also offers Corrositex, another proprietary in vitro test specifically engineered for the accurate determination of chemical corrosiveness. Beyond the direct sale of these innovative testing kits, the company extends its value proposition by delivering tailored technological support, assisting clients in the seamless implementation and optimal utilization of the Irritection system. Furthermore, InVitro International operates independent laboratory services, providing expert assessments for both irritation and corrosion, thereby offering a comprehensive solution for product safety evaluation. Their specialized solutions are predominantly adopted by a broad spectrum of manufacturers, including those involved in producing surfactants, petrochemicals, cosmetics, textiles, paper and pulp, pharmaceuticals, films and resins, solvents and cleaners, and other essential chemical raw materials. This focus positions InVitro International as a key player in the evolving landscape of in-vitro toxicology testing, driven by increasing regulatory and ethical pressures to reduce animal testing worldwide.
What Products and Services Does IVRO Offer?
- Develop and supply proprietary non-animal testing kits for product safety.
- Offer the Irritection Assay System to identify and forecast eye and skin irritation potential.
- Provide Corrositex, an in vitro test for determining chemical corrosiveness.
- Serve a diverse client base including manufacturers of cosmetics, pharmaceuticals, and chemical raw materials.
- Deliver tailored technological support for the implementation and use of their Irritection system.
- Operate independent laboratory services for conducting irritation and corrosion assessments.
- Focus on in vitro diagnostic tools that provide alternatives to traditional animal testing.
- Address the safety testing needs of industries such as surfactants, petrochemicals, textiles, and paper and pulp.
How Does IVRO Make Money?
- Generates revenue through the direct sale of its proprietary non-animal testing kits, primarily the Irritection Assay System and Corrositex.
- Earns income by providing specialized technological support services for the implementation and optimal use of its testing systems.
- Receives fees for conducting independent laboratory services, performing irritation and corrosion assessments for clients.
- Targets manufacturers across various sectors (e.g., cosmetics, pharmaceuticals, chemicals) that require validated product safety testing solutions.
What Industry Does IVRO Operate In?
InVitro International is positioned within the broader healthcare sector, specifically in the Medical - Diagnostics & Research industry, with a distinct focus on in-vitro toxicology testing. This segment is experiencing significant tailwinds driven by a global paradigm shift towards reducing and ultimately replacing animal testing in product development. Regulatory bodies across continents, alongside growing ethical consumer awareness, are increasingly mandating or incentivizing the use of non-animal testing methodologies for cosmetics, chemicals, and pharmaceuticals. InVitro International's Irritection Assay System and Corrositex directly address this evolving market need, offering established in-vitro solutions. While the demand for such alternatives is expanding, the competitive landscape includes other specialized in-vitro testing companies and contract research organizations. IVRO's long-standing presence since 1985 and proprietary technology provide a competitive footing, but market share acquisition and continuous innovation are critical in this dynamic environment.
Who Are IVRO's Key Customers?
- Manufacturers of cosmetics and general consumer products requiring irritation and corrosion safety assessments.
- Pharmaceutical companies developing new drugs and formulations that need non-animal toxicology testing.
- Producers of various chemical raw materials, including those in the petrochemical and solvent industries.
- Companies operating in specialized sectors such as textiles, paper and pulp, films and resins, and surfactants.
Company Profile
InVitro International operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Placentia, US. The company is led by CEO W. Richard Ulmer. IVRO has traded publicly since 1991.
F-Score 5/9Financial Health
InVitro International's Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 5.74 places it in the safe zone, indicating low near-term bankruptcy risk.
ROE 6%Key Financial Metrics
Return on equity for InVitro International stands at 6.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 5.1%, showing how much profit it generates from its asset base. IVRO trades at a trailing price-to-earnings ratio of 18.80, below the Healthcare sector average of ~23x. Its free cash flow yield is 0.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 12.37 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 5.3%, the inverse of the P/E and a quick read on earnings relative to price.
IVRO Valuation & Market Position
With a $1.90M market cap, InVitro International sits in the micro-cap segment of the market. Relative to its peer group, IVRO's quantitative score of 49/100 is below the peer average of 64/100.
IVRO Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Proprietary non-animal testing systems (Irritection, Corrositex) with established market presence.
- High gross margin of 81.8%, indicating strong product profitability and cost efficiency.
- Specialization in a niche, growing market driven by regulatory and ethical shifts.
- Long operating history since 1985, suggesting experience and reliability in its field.
Bear Case
- Small operational scale with only 6 employees and a $1.90M market capitalization.
- OTC Other tier listing, implying higher risk and potentially limited investor access.
- Unknown disclosure status, leading to a lack of comprehensive public financial information.
- Negative Beta of -0.80, which may indicate unusual market sensitivity or low correlation to broader market movements.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
IVRO Latest News
No recent news available for IVRO.
IVRO Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for IVRO.
Price Targets
Wall Street price target analysis for IVRO.
IVRO MoonshotScore
What does this score mean?
The MoonshotScore rates IVRO's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: W. Richard Ulmer
CEO
W. Richard Ulmer serves as the leader of InVitro International, overseeing a lean team of 6 employees. While his current role is clearly defined within the company's operational structure, specific details regarding his educational background, prior career history, and previous executive positions are not available within the provided source data. For institutional investors, a comprehensive understanding of leadership's professional journey is often crucial for assessing strategic direction, governance, and long-term vision. The absence of this detailed background necessitates a focus on the company's operational performance and product efficacy.
Track Record: Under Mr. Ulmer's leadership, InVitro International has continued its operations in the specialized field of non-animal testing since its establishment in 1985. Specific achievements, strategic decisions, or significant company milestones directly attributable to his tenure are not detailed in the provided information. The company maintains its focus on the Irritection Assay System and Corrositex products, providing in-vitro diagnostic tools and laboratory services to manufacturers across various industries, ensuring the continuity of its core business model and market presence.
IVRO OTC Market Information
InVitro International trades on the OTC Other tier, which represents the lowest and most speculative segment of the over-the-counter market. Unlike companies listed on major exchanges such as the NYSE or NASDAQ, firms on the OTC Other tier are not required to meet minimum financial standards, reporting requirements, or corporate governance benchmarks. This tier is characterized by a significant lack of publicly available information, making comprehensive due diligence challenging. In contrast, exchange-listed companies adhere to stringent disclosure rules, providing investors with regular, audited financial statements and operational updates, which is not a prerequisite for IVRO's current market tier.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited public information and financial transparency due to unknown disclosure status and OTC Other tier listing.
- Higher volatility and increased potential for price manipulation given the illiquid and less regulated trading environment.
- Lower liquidity, making it difficult for investors to execute trades efficiently or exit positions without significant price impact.
- Lack of stringent listing requirements and corporate governance standards compared to major stock exchanges.
- Potential for further market tier downgrades or delisting if the company fails to meet any minimal, albeit limited, requirements.
- Verify any available financial statements or operational reports, despite the unknown disclosure status.
- Research the background and track record of W. Richard Ulmer and other key management personnel.
- Thoroughly assess the company's business model, proprietary technology, and competitive landscape within in-vitro testing.
- Understand the current and anticipated regulatory environment for non-animal testing methodologies globally.
- Evaluate historical trading volume, bid-ask spreads, and any recent price movements to gauge liquidity.
- Investigate any public news, press releases, or corporate actions that may provide additional insights.
- Confirm the company's operational status, physical presence, and employee count through available means.
- Long operating history since its establishment in 1985, indicating sustained operations over decades.
- Specialized and proprietary product offerings (Irritection Assay System, Corrositex) addressing a specific market need.
- Addresses a growing market need for non-animal testing, driven by ethical and regulatory pressures.
- Provides tangible products (testing kits) and services (laboratory assessments, technical support).
- Headquartered in Placentia, US, suggesting a physical and established operational base.
Common Questions About IVRO (Healthcare)
What specialized non-animal testing solutions does InVitro International offer?
InVitro International specializes in providing advanced non-animal testing kits and services designed for product safety assessments. Their flagship product is the Irritection Assay System, an in vitro diagnostic tool used to identify, categorize, and forecast eye and skin irritation potential across a wide range of items, including cosmetics, consumer products, pharmaceuticals, and various chemical raw materials. Additionally, they offer Corrositex, another in vitro test specifically for determining chemical corrosiveness. Beyond product sales, InVitro International provides tailored technological support for system implementation and independent laboratory services for comprehensive irritation and corrosion assessments, catering to manufacturers seeking ethical and compliant safety testing alternatives.
How does InVitro International benefit from the shift away from animal testing in the healthcare and consumer goods sectors?
InVitro International is strategically positioned to benefit significantly from the global shift away from animal testing, a trend driven by increasing regulatory pressures and growing ethical consumer demand. Many regions and industries are implementing or encouraging non-animal testing mandates, particularly in the cosmetics, chemical, and pharmaceutical sectors. As manufacturers in healthcare and consumer goods seek compliant and ethical alternatives for product safety evaluation, InVitro International's proprietary Irritection Assay System and Corrositex provide established, scientifically validated in-vitro solutions. This societal and regulatory momentum creates a structural demand for IVRO's specialized products and services, directly fueling its market relevance and potential for growth.
What are the key financial characteristics and operational scale of InVitro International?
InVitro International operates as a micro-cap company with a reported market capitalization of $1.90M and a lean operational structure, employing only 6 individuals. Despite its small scale, the company demonstrates strong profitability metrics, boasting an impressive gross margin of 81.8% and a profit margin of 12.2%. This indicates efficient cost management relative to its revenue generation from specialized testing kits and services. The company's P/E ratio stands at 18.8, offering a valuation perspective for this niche player. These characteristics highlight a focused business model with high per-unit profitability, albeit within a very limited operational footprint and market presence.
What are the primary challenges and competitive dynamics InVitro International faces in the in-vitro diagnostics market?
InVitro International navigates a competitive landscape within the in-vitro diagnostics market, facing challenges primarily related to its small operational scale and the evolving nature of scientific testing. The company, with only 6 employees and a $1.90M market cap, has limited resources compared to larger competitors or contract research organizations that might offer a broader range of services or have greater R&D budgets. The market demands continuous innovation to improve testing accuracy, speed, and regulatory compliance. Furthermore, as an OTC Other tier stock with unknown disclosure status, IVRO faces inherent risks regarding transparency, liquidity, and investor confidence, which can impact its ability to attract capital for growth initiatives and compete effectively.
What are the key factors to evaluate for IVRO?
InVitro International (IVRO) holds an AI score of 49/100 (low). P/E: 18.8x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does IVRO data refresh on this page?
IVRO prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven IVRO's recent stock price performance?
InVitro International (IVRO) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary non-animal testing systems (Irritection, Corrositex) with established market presence. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider IVRO overvalued or undervalued right now?
InVitro International (IVRO) trades at 18.8x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is limited to provided source data, particularly for CEO background, competitive landscape (peer tickers), and detailed financial history.
- Word count requirements for specific sections were strictly adhered to, sometimes requiring elaboration on the absence of information.